Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Reversing neuronal cell vulnerability common to three types of ataxias: Christianson Syndrome, Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), and Spinocerebellar ataxia type 6 (SCA6)
EF 2022-23
Résumé
Cerebellar ataxias are devasting disorders involving progressive movement impairment. Different forms of ataxia arise from various mutations in several genes, yet the disease progress can be similar. Most ataxias are rare, affecting tens of thousands worldwide. As the market is too small, Pharma is not interested in investigating it. Yet no treatments currently exist. I will study three different rare ataxias: Autosomal Recessive Spastic Ataxia of the Charlevoix-Saguenay (ARSACS), Christianson syndrome (CS), and Spinocerebellar ataxia type 6 (SCA6). These ataxias have common patterns of cell dysfunction and death despite having different causes. By studying these ataxias in parallel, we want to set the bar for comparative disease research. This project aims to identify common cellular alterations leading to cell death in three distinct forms of ataxia: CS, ARSACS, and SCA6. I hypothesize that there are common cellular mechanisms in the anterior cerebellum in multiple ataxias and targeting them will lead to novel therapeutic approaches. I expect this proposal to produce new high-impact findings that will transform preclinical research for these diseases. I aim to classify various neurodegenerative ataxias in a new manner according to the pattern of cell vulnerability and exhibited resilience. This will allow the identification of shared markers that confer selective neuron vulnerability. I will test new therapeutic targets for the treatment of these ataxias. As these neurodegenerative diseases are rare, it is advantageous to target shared disease mechanisms so that pharmaceutical companies are more likely to invest in these therapeutics.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
498209
Name
Kanagasabai Atchaya
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Reversing neuronal cell vulnerability common to three types of ataxias: Christianson Syndrome, Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), and Spinocerebellar ataxia type 6 (SCA6)
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Arsacs; Ataxia; Cerebellum; Christianson Syndrome; Eaat1; Endosomes; Neurodegeneration; Nhe6; Purkinje Cells; Sca6
Abstract
Cerebellar ataxias are devasting disorders involving progressive movement impairment. Different forms of ataxia arise from various mutations in several genes, yet the disease progress can be similar. Most ataxias are rare, affecting tens of thousands worldwide. As the market is too small, Pharma is not interested in investigating it. Yet no treatments currently exist. I will study three different rare ataxias: Autosomal Recessive Spastic Ataxia of the Charlevoix-Saguenay (ARSACS), Christianson syndrome (CS), and Spinocerebellar ataxia type 6 (SCA6). These ataxias have common patterns of cell dysfunction and death despite having different causes. By studying these ataxias in parallel, we want to set the bar for comparative disease research. This project aims to identify common cellular alterations leading to cell death in three distinct forms of ataxia: CS, ARSACS, and SCA6. I hypothesize that there are common cellular mechanisms in the anterior cerebellum in multiple ataxias and targeting them will lead to novel therapeutic approaches. I expect this proposal to produce new high-impact findings that will transform preclinical research for these diseases. I aim to classify various neurodegenerative ataxias in a new manner according to the pattern of cell vulnerability and exhibited resilience. This will allow the identification of shared markers that confer selective neuron vulnerability. I will test new therapeutic targets for the treatment of these ataxias. As these neurodegenerative diseases are rare, it is advantageous to target shared disease mechanisms so that pharmaceutical companies are more likely to invest in these therapeutics.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kanagasabai, Atchaya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~